• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Veracyte Inc.

    11/10/25 9:04:40 AM ET
    $VCYT
    Medical Specialities
    Health Care
    Get the next $VCYT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    VERACYTE INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    92337F107

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    92337F107


    1Names of Reporting Persons

    STATE STREET CORPORATION
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,938,903.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,199,674.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,199,674.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.3 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    VERACYTE INC
    (b)Address of issuer's principal executive offices:

    6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO, CALIFORNIA, 94080, UNITED STATES
    Item 2. 
    (a)Name of person filing:

    STATE STREET CORPORATION;
    (b)Address or principal business office or, if none, residence:

    ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
    (c)Citizenship:

    MA
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    92337F107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4199674.00
    (b)Percent of class:

    5.3  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    3,938,903

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    4,199,674

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    NOT APPLICABLE
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    NOT APPLICABLE
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    NOT APPLICABLE

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    STATE STREET CORPORATION
     
    Signature:ELIZABETH SCHAEFER
    Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
    Date:11/07/2025
    Get the next $VCYT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VCYT

    DatePrice TargetRatingAnalyst
    12/2/2025$48.00Underweight
    Morgan Stanley
    10/20/2025$40.00Hold
    Canaccord Genuity
    3/20/2025$45.00Buy
    Craig Hallum
    12/5/2024$38.00 → $37.00Buy → Neutral
    Goldman
    11/15/2024$50.00Outperform
    Wolfe Research
    10/16/2024$43.00Buy
    UBS
    10/10/2024$40.00Buy
    Guggenheim
    2/23/2024$30.00 → $33.00Buy
    Needham
    More analyst ratings

    $VCYT
    SEC Filings

    View All

    Veracyte Inc. filed SEC Form 8-K: Leadership Update

    8-K - VERACYTE, INC. (0001384101) (Filer)

    3/16/26 4:17:01 PM ET
    $VCYT
    Medical Specialities
    Health Care

    SEC Form 144 filed by Veracyte Inc.

    144 - VERACYTE, INC. (0001384101) (Subject)

    3/4/26 4:37:55 PM ET
    $VCYT
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Veracyte Inc.

    10-K - VERACYTE, INC. (0001384101) (Filer)

    2/26/26 4:32:29 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Chambers Rebecca was granted 49,338 shares, increasing direct ownership by 38% to 180,534 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    3/10/26 5:09:57 PM ET
    $VCYT
    Medical Specialities
    Health Care

    SEC Form 4 filed by Veracyte Inc.

    4 - VERACYTE, INC. (0001384101) (Issuer)

    3/10/26 5:10:03 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Chief Scientific & Med Officer Febbo Phillip G. was granted 36,181 shares, increasing direct ownership by 31% to 153,527 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    3/10/26 5:10:19 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Veracyte with a new price target

    Morgan Stanley resumed coverage of Veracyte with a rating of Underweight and set a new price target of $48.00

    12/2/25 8:36:20 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Canaccord Genuity initiated coverage on Veracyte with a new price target

    Canaccord Genuity initiated coverage of Veracyte with a rating of Hold and set a new price target of $40.00

    10/20/25 8:47:51 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Craig Hallum initiated coverage on Veracyte with a new price target

    Craig Hallum initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00

    3/20/25 7:42:48 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veracyte Names Kevin Haas as Chief Development and Technology Officer

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company's global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company's end‑to‑end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316934398/en/Veracyte Names Kevin Haas as Chief De

    3/16/26 4:15:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

    Grew fourth quarter total revenue to $140.6 million, an increase of 19% Grew fourth quarter testing revenue to $135.8 million, an increase of 21% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025. "We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter," said Marc Stapley, Veracyte's chief executive officer. "We are achieving this growth while maintaining best-in-class profitability, with mo

    2/25/26 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

    More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and Bladder tests Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today more than 15 abstracts featuring its urology portfolio will be presented at the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU). The abstracts span studies across prostate and bladder cancers, featuring real-world data for Decipher Prostate and new insights from phase II clinical trials, including one utilizing the company's upcoming TrueMRD™ Muscle-Invasive Bladder Cancer (MIBC) test. Collectively, these studies highlight how Veracyte's De

    2/24/26 9:00:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Leadership Updates

    Live Leadership Updates

    View All

    Veracyte Names Kevin Haas as Chief Development and Technology Officer

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company's global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company's end‑to‑end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316934398/en/Veracyte Names Kevin Haas as Chief De

    3/16/26 4:15:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Set to Join S&P SmallCap 600

    NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE:TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners LLC will acquire Triumph Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 29, 2025 S&P SmallCap 600 Addition Veracyte VCYT Health Care July 29, 2025 S&P SmallCap 600 Deletion Triumph Group TGI Industrials For more information about S&P Dow Jones Indices,

    7/24/25 5:58:00 PM ET
    $SPGI
    $TGI
    $VCYT
    Finance: Consumer Services
    Finance
    Aerospace
    Industrials

    Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac

    9/4/24 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Financials

    Live finance-specific insights

    View All

    Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

    Grew fourth quarter total revenue to $140.6 million, an increase of 19% Grew fourth quarter testing revenue to $135.8 million, an increase of 21% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025. "We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter," said Marc Stapley, Veracyte's chief executive officer. "We are achieving this growth while maintaining best-in-class profitability, with mo

    2/25/26 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/motsphxv. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://inv

    2/4/26 5:15:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Announces Third Quarter 2025 Financial Results

    Grew total revenue to $131.9 million and testing revenue to $127.8 million, representing increases of 14% and 17% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. "We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance," said Marc Stapley, Veracyte's chief executive officer. "We continue to advance our mission of transforming cancer care by generating high-quality evidence and clinical insights tha

    11/4/25 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veracyte Inc.

    SC 13G - VERACYTE, INC. (0001384101) (Subject)

    11/12/24 9:30:49 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

    SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

    11/8/24 10:41:07 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

    SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

    10/2/24 2:12:30 PM ET
    $VCYT
    Medical Specialities
    Health Care